ArticleCureus2025
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-oncology (IO) therapies, particularly immune checkpoint inhibitors, have significantly altered the treatment landscape for various cancers, including renal cell carcinoma (RCC). Unfortunately, immune-related adverse events (irAEs) during therapy often necessitate corticosteroid intervention, which may theoretically impair the anti-tumor immune response. In this article, we describe a unique case in which a patient with advanced papillary RCC developed immune-related myasthenia gravis (MG) while on nivolumab (a PD-1 inhibitor) and cabozantinib. Even while giving corticosteroid treatment for myasthenia gravis, the patient exhibited a striking treatment response, with substantial tumor shrinkage and regression of regional lymphadenopathy. This case highlights that IO agents can remain efficacious even in the presence of significant immunosuppression, raising important mechanistic and clinical considerations for managing irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.